UnknownNot Applicable

CHA2DS2-VASc Score as a Predictor of Thrombus Burden and Clinical Outcomes in Patients Undergoing PPCI.

184 participantsStarted 2021-01

Plain-language summary

Aim of the work is to evaluate the use CHA2DS2-VASc score in predicting no-reflow phenomenon and its impact on short term primary percutaneous coronary intervention outcomes (in-hospital mortality) and long term (6 months) incidence of MACE ( major adverse cardiac event ) in patients with ST segment elevation Myocardial infarction who underwent primary primary percutaneous coronary intervention

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects with STEMI and undergoing primary Primary percutaneous coronary intervention. * Patient Loaded pre-procedural with using with Aspirin 300 mg plus Ticagrelor 180 mg or Clopidogrel 600 mg. Exclusion Criteria: * Patients with chest pain more than 48 hours * Patients not eligible for primary PCI

What they're measuring

TIMI (Thrombolysis in myocardial infarction) flow after Primary Percutaneous Coronary Intervention (No-reflow phenomenon versus normal flow)

Timeframe: Baseline

Trial details

NCT IDNCT04565808

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-04

Contact for this trial

Osman Ahmed Osman Ahmed, MBBCH/MBBS

+20 01068988494 drosmanahmed1994@gmail.com

View on ClinicalTrials.gov More STEMI trials